Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07819864

Diaphragm Hibernation and Its Driving Factors in Mechanically Ventilated ICU Patients

Rationale:

Patients with invasive mechanical ventilation (IMV) frequently develop diaphragm dysfunction and experience difficult weaning. Recent ex vivo work suggests that a subset of mechanically ventilated ICU patients may exhibit diaphragm hibernation, an energy conserving myosin state that reduces force generation and may lead to a reversible increase in diaphragm strength over time. However, it is unknown whether diaphragm hibernation can be demonstrated in vivo during IMV and which clinical and biological factors are associated with this phenotype.

Objective:

Primary objective is to determine the driving factors (biomarkers) of diaphragm hibernation during IMV. Secondary objectives are to determine the proportion of ventilated critically ill patients who exhibit diaphragm hibernation during IMV, to investigate inflammatory and metabolic factors and other clinical exposures associated with diaphragm hibernation, and to explore associations between diaphragm hibernation and weaning related and survival outcomes.

Study design:

Prospective, observational, longitudinal cohort study.

Study population:

Adult ICU patients receiving IMV, expected to remain mechanically ventilated for at least 72 hours.

Intervention (if applicable):

Not applicable. This is an observational study. Study specific procedures consist of repeated phrenic nerve magnetic stimulation and additional blood sampling.

Main study parameters/endpoints:

The primary study parameter is the proportion of participants exhibiting diaphragm hibernation during IMV. Diaphragm hibernation is defined as an increase in stimulated twitch tracheal pressure (Ptr,stim), a measure of diaphragm strength, of at least 10% relative to baseline (Day 0-1) at any follow up assessment (Day 2, 3, 5, or 7) obtained before extubation or death. Ptr,stim will be assessed repeatedly on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

Participant burden is limited and mainly consists of repeated phrenic nerve magnetic stimulation during a ventilator delivered end expiratory occlusion and additional blood sampling of 9.5 mL per time point, up to a total of 47.5 mL across the study period. Magnetic stimulation is non-invasive and expected discomfort is transient. Rare transient physiological changes may occur and measurements are performed under continuous ICU monitoring and will be postponed or omitted if considered unsafe or interfering with clinical care. Direct benefit for participants is limited, but the study may provide clinically relevant knowledge on diaphragm hibernation and its driving factors. The research questions are specific to diaphragm physiology during IMV in critically ill patients, therefore the study is group related and cannot be performed in a different population.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Radboud University Medical Center (Radboudumc)

Nijmegen, Gelderland, 6525 GA, Netherlands

Location contact

Jonne Doorduin, PhD

CONTACT

[email protected]

0031650155757

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years.
  • Receiving invasive mechanical ventilation at screening.
  • Expected to remain mechanically ventilated for ≥ 72 hours from enrolment.
  • The first study assessment can be performed within 36 hours after initiation of invasive mechanical ventilation.

Exclusion criteria

  • Pre-existing neuromuscular disease affecting the diaphragm (e.g. motor neuron disease, myasthenia gravis, advanced muscular dystrophy, high cervical spinal cord injury) or use of neuromuscular blocker.
  • Known phrenic nerve palsy or prior diaphragmatic paralysis.
  • Long-term home mechanical ventilation (invasive or non-invasive) prior to ICU admission.
  • Post-operative patients after planned diaphragm or phrenic nerve surgery.
  • Contraindications to phrenic nerve magnetic stimulation (e.g., unstable cervical spine injury, uncontrolled intracranial hypertension, metallic implants in stimulation area as per manufacturer guidance).
  • Pregnancy.
  • Participation in another interventional trial that explicitly prohibits co-enrolment or is expected to substantially influence diaphragm function (e.g. experimental neuromuscular blocking strategies), as decided by the principal investigator.

Treatment and study plan

Primary outcomes

  1. Blood C reactive protein level

    Time frame: C reactive protein will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.

    C reactive protein will be assessed by blood sample.

  2. Blood procalcitonin level

    Time frame: Procalcitonin will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.

    Procalcitonin will be assessed by blood sample.

  3. Blood metabolic biomarkers level

    Time frame: Metabolic biomarkers will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.

    Metabolic biomarkers will be assessed by blood sample using OLINK Target 96 panel.

  4. Blood TNF-α level

    Time frame: TNF-α will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.

    TNF-α will be assessed by blood sample.

  5. Blood IL-10 level

    Time frame: IL-10 will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.

    IL-10 will be assessed by blood sample.

  6. Blood IL-8 level

    Time frame: IL-8 will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.

    IL-8 will be assessed by blood sample.

  7. Blood IL-6 level

    Time frame: IL-6 will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.

    IL-6 will be assessed by blood sample.

  8. Blood ferritin level

    Time frame: Ferritin will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.

    Ferritin will be assessed by blood sample.

Secondary outcomes

  1. Proportion of participants exhibiting diaphragm hibernation during invasive mechanical ventilation

    Time frame: Ptr,stim will be assessed repeatedly on Day 0 to 1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.

    Diaphragm hibernation is defined as an increase in stimulated twitch tracheal pressure (Ptr,stim), a measure of diaphragm strength, of at least 10% relative to baseline (Day 0 to 1) at any follow up assessment (Day 2, 3, 5, or 7) obtained before extubation or death.

  2. Number of days from intubation to successful extubation

    Time frame: Collected from study inclusion until Day 28, or ICU/hospital discharge or death, whichever occurs first

    Data about number of days from intubation to successful extubation will be retrieved from electronic medical records.

  3. Number of days from first SBT to successful extubation

    Time frame: Collected from study inclusion until Day 28, or ICU/hospital discharge or death, whichever occurs first

    Data about number of days from first SBT to successful extubation will be retrieved from electronic medical records.

  4. Incidence of weaning failure

    Time frame: Collected from study inclusion until Day 28, or ICU/hospital discharge or death, whichever occurs first

    Weaning failure is defined as SBT failure or reintubation within 48 hours. Data will be retrieved from electronic medical records.

  5. ICU length of stay

    Time frame: Collected from study inclusion until Day 28, or ICU discharge or death, whichever occurs first

    Data about ICU length of stay will be retrieved from electronic medical records.

  6. Hospital length of stay

    Time frame: Collected from study inclusion until Day 28, or hospital discharge or death, whichever occurs first

    Data about hospital length of stay will be retrieved from electronic medical records.

  7. ICU mortality

    Time frame: Collected from study inclusion until Day 28, or ICU discharge or death, whichever occurs first

    Data about ICU mortality will be retrieved from electronic medical records.

  8. Hospital mortality

    Time frame: Collected from study inclusion until Day 28, or hospital discharge or death, whichever occurs first

    Data about hospital mortality will be retrieved from electronic medical records.

  9. Day 28 all-cause mortality

    Time frame: Collected from study inclusion until Day 28 or death, whichever occurs first

    Data about day 28 all-cause mortality will be retrieved from electronic medical records.

  10. ICU-free days through day 28

    Time frame: Collected from ICU discharge until Day 28 or death, whichever occurs first

    Data about ICU-free days through day 28 will be retrieved from electronic medical records.

  11. Hospital-free days through day 28

    Time frame: Collected from hospital discharge until Day 28 or death, whichever occurs first

    Data about hospital-free days through day 28 will be retrieved from electronic medical records.

  12. Time to ICU discharge alive through day 28

    Time frame: Collected from study inclusion until Day 28, or ICU discharge or death, whichever occurs first

    Data about time to ICU discharge alive through day 28 will be retrieved from electronic medical records.

  13. Time to hospital discharge alive through day 28

    Time frame: Collected from study inclusion until Day 28, or hospital discharge or death, whichever occurs first

    Data about time to hospital discharge alive through day 28 will be retrieved from electronic medical records.

Study contacts

Contact information is provided by the study sponsor or research team.

Jinyu Zhou, M.sc.

CONTACT

[email protected]

0031626194204

Sponsors and collaborators

Lead sponsor

Radboud University Medical Center

Other

Registry information

Official study title

Diaphragm hIbernation and itS Driving factorS in mEChanically venTilated ICU Patients: the DISSECT Study

Acronym: DISSECT

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Sep 15, 2026
Registry last updated
Sep 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.